Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children
W. Borkowsky et al., Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children, J INFEC DIS, 182(1), 2000, pp. 96-103
The response of 40 immunologic parameters was studied for 147 clinically st
able, protease inhibitor-naive, human immunodeficiency virus (HIV)-infected
children aged 2-17 years when antiretroviral therapy was changed to either
a dual nucleoside analogue regimen or a protease inhibitor-containing regi
men. Immunologic response to therapy, as measured by lymphocyte subsets, 3-
color flow cytometric measures, and lymphoproliferative assays, were invest
igated for changes in weeks 44 and 48, The most significant changes after b
aseline that were associated with the administration of a protease inhibito
r-containing regimen were seen for percentages of CD8(+)/CD38(+)/HLA-DR+, C
D8(+)/CD95(+)/CD28(-), and CD8, The percentages of CD8(+)/CD38(+)/HLA-DR+ a
nd CD8(+)/CD95(+)/CD28(-) decreased from baseline medians of 33% and 46% to
medians of 18% and 30% at week 44 (P < .0001 for both). Median CD4 cell co
unt increased 168 cells/mu L (from 694 cells/mu L to 862 cells/mu L; P = .0
2) by week 48 in this clinically stable population. Changes in lymphoprolif
erative responses to HIV antigens and recall antigens did not increase over
time and between groups.